Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Plectin-1 as a novel biomarker for pancreatic cancer.

Bausch D, Thomas S, Mino-Kenudson M, Fernández-del CC, Bauer TW, Williams M, Warshaw AL, Thayer SP, Kelly KA.

Clin Cancer Res. 2011 Jan 15;17(2):302-9. doi: 10.1158/1078-0432.CCR-10-0999. Epub 2010 Nov 23.

2.

Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1.

Foygel K, Wang H, Machtaler S, Lutz AM, Chen R, Pysz M, Lowe AW, Tian L, Carrigan T, Brentnall TA, Willmann JK.

Gastroenterology. 2013 Oct;145(4):885-894.e3. doi: 10.1053/j.gastro.2013.06.011. Epub 2013 Jun 18.

3.

111In-Tetrameric Plectin-1 targeting peptide (4(βAKTLLPTP-GGS(PEG5000))KKK-111In-DOTA-βA-NH2).

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Jan 28 [updated 2011 Apr 27].

4.

Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models.

Cruz-Monserrate Z, Abd-Elgaliel WR, Grote T, Deng D, Ji B, Arumugam T, Wang H, Tung CH, Logsdon CD.

Gut. 2012 Sep;61(9):1315-22. doi: 10.1136/gutjnl-2011-300544. Epub 2011 Nov 7.

5.

Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.

Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV.

Arch Pathol Lab Med. 2014 Feb;138(2):220-8. doi: 10.5858/arpa.2013-0056-OA.

6.

Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma.

Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H, Depinho RA, Mahmood U, Weissleder R.

PLoS Med. 2008 Apr 15;5(4):e85. doi: 10.1371/journal.pmed.0050085.

7.

CRABP-II is a highly sensitive and specific diagnostic molecular marker for pancreatic ductal adenocarcinoma in distinguishing from benign pancreatic conditions.

Xiao W, Hong H, Awadallah A, Yu S, Zhou L, Xin W.

Hum Pathol. 2014 Jun;45(6):1177-83. doi: 10.1016/j.humpath.2014.01.014. Epub 2014 Jan 31.

8.

MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.

Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ Jr, Suriawinata AA, Tsongalis GJ.

Cancer Genet. 2013 Jun;206(6):217-21. doi: 10.1016/j.cancergen.2013.05.020. Epub 2013 Aug 9.

PMID:
23933230
9.

Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.

Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, Fendrich V, Ring J, Sipos B, Tuveson DA, Bremer C, Gress TM, Michl P.

Gut. 2013 Jul;62(7):1034-43. doi: 10.1136/gutjnl-2012-302577. Epub 2012 Jun 7.

PMID:
22677720
10.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

11.

Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma.

Wachter DL, Schlabrakowski A, Hoegel J, Kristiansen G, Hartmann A, Riener MO.

Am J Surg Pathol. 2011 Jun;35(6):873-7. doi: 10.1097/PAS.0b013e3182189223.

PMID:
21566520
12.

Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.

Chung JC, Oh MJ, Choi SH, Bae CD.

ANZ J Surg. 2008 Apr;78(4):245-51. doi: 10.1111/j.1445-2197.2008.04429.x.

PMID:
18366394
13.

MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer.

Grüner BM, Hahne H, Mazur PK, Trajkovic-Arsic M, Maier S, Esposito I, Kalideris E, Michalski CW, Kleeff J, Rauser S, Schmid RM, Küster B, Walch A, Siveke JT.

PLoS One. 2012;7(6):e39424. doi: 10.1371/journal.pone.0039424. Epub 2012 Jun 26.

14.

Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.

Munding JB, Adai AT, Maghnouj A, Urbanik A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, Tannapfel A, Hahn SA.

Int J Cancer. 2012 Jul 15;131(2):E86-95. doi: 10.1002/ijc.26466. Epub 2011 Nov 19.

15.

Monitoring pancreatic carcinogenesis by the molecular imaging of cathepsin E in vivo using confocal laser endomicroscopy.

Li H, Li Y, Cui L, Wang B, Cui W, Li M, Cheng Y.

PLoS One. 2014 Sep 3;9(9):e106566. doi: 10.1371/journal.pone.0106566. eCollection 2014.

16.

Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma.

Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, Schirrmacher P, Klöppel G, Altevogt P, Schäfer H, Sebens Müerköster S.

Oncol Rep. 2010 Oct;24(4):909-15.

PMID:
20811670
17.

Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.

Hocker JR, Postier RG, Li M, Lerner MR, Lightfoot SA, Peyton MD, Deb SJ, Baker CM, Williams TL, Hanas RJ, Stowell DE, Lander TJ, Brackett DJ, Hanas JS.

Cancer Lett. 2015 Apr 10;359(2):314-24. doi: 10.1016/j.canlet.2015.01.035. Epub 2015 Jan 28.

18.

Synthesis and evaluation of a radioiodinated peptide probe targeting αvβ6 integrin for the detection of pancreatic ductal adenocarcinoma.

Ueda M, Fukushima T, Ogawa K, Kimura H, Ono M, Yamaguchi T, Ikehara Y, Saji H.

Biochem Biophys Res Commun. 2014 Mar 14;445(3):661-6. doi: 10.1016/j.bbrc.2014.02.086. Epub 2014 Feb 26.

PMID:
24583127
19.

Targeting pancreatic ductal adenocarcinoma acidic microenvironment.

Cruz-Monserrate Z, Roland CL, Deng D, Arumugam T, Moshnikova A, Andreev OA, Reshetnyak YK, Logsdon CD.

Sci Rep. 2014 Mar 19;4:4410. doi: 10.1038/srep04410.

20.

SERPINB5 Promoter Hypomethylation Differentiates Pancreatic Ductal Adenocarcinoma From Pancreatitis.

Mardin WA, Ntalos D, Mees ST, Spieker T, Senninger N, Haier J, Dhayat SA.

Pancreas. 2016 May-Jun;45(5):743-7. doi: 10.1097/MPA.0000000000000526.

PMID:
26646275

Supplemental Content

Support Center